MetaCap

AgomAb Therapeutics NV (AGMB) vs SAB Biotherapeutics (SABS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $253.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%SABS-32.61%
+26%-21%-67%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%SABS-32.61%
+13%-27%-66%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus SABS key metrics
MetricAGMBSABS
Share price$5.45$2.81
Market cap$268.40M$253.15M
1-day change-3.02%-3.44%
YTD return—-24.87%
1-year return—-28.86%
5-year return—-97.32%
EPS (TTM)$-2.08$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)—$13.27M
52-week high$17.82$5.15
52-week low$5.39$2.44
Distance from 52-week high-69.42%-45.44%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+591.19%+314.23%
Average volume208.99K633.60K
Shares outstanding49.25M90.09M
Employees6286
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

AGMB vs SABS FAQ

Which is bigger, AgomAb Therapeutics NV or SAB Biotherapeutics?

AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $253.15M for SAB Biotherapeutics (SABS).

Are AgomAb Therapeutics NV and SAB Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons